About Liprin-alpha-2
Liprin-alpha-2 (PPFIA2) is a protein
from Homo sapiens identified by UniProt accession
O75334, 1257 residues long.
MolForge cross-references it against 0 known binders and
84 disease associations.
Target properties
| Protein name | Liprin-alpha-2 |
|---|
| UniProt accession | O75334 |
|---|
| Gene | PPFIA2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1257 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (84)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.42
- urate measurement · score 0.37
- bone density · score 0.37
- mathematical ability · score 0.36
- self reported educational attainment · score 0.34
- diet measurement · score 0.33
- glomerular filtration rate · score 0.28
- neuroinflammatory disorder · score 0.28
- cognitive function measurement · score 0.27
- resting heart rate · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75334-F1 | alphafold | PREDICTED | 65.99 | — |
Amino-acid sequence (1257 residues)
MMCEVMPTIN EDTPMSQRGS QSSGSDSDSH FEQLMVNMLD ERDRLLDTLR ETQESLSLAQ QRLQDVIYDR DSLQRQLNSA LPQDIESLTG GLAGSKGADP PEFAALTKEL NACREQLLEK EEEISELKAE RNNTRLLLEH LECLVSRHER SLRMTVVKRQ AQSPSGVSSE VEVLKALKSL FEHHKALDEK VRERLRVSLE RVSALEEELA AANQEIVALR EQNVHIQRKM ASSEGSTESE HLEGMEPGQK VHEKRLSNGS IDSTDETSQI VELQELLEKQ NYEMAQMKER LAALSSRVGE VEQEAETARK DLIKTEEMNT KYQRDIREAM AQKEDMEERI TTLEKRYLSA QRESTSIHDM NDKLENELAN KEAILRQMEE KNRQLQERLE LAEQKLQQTM RKAETLPEVE AELAQRIAAL TKAEERHGNI EERMRHLEGQ LEEKNQELQR ARQREKMNEE HNKRLSDTVD RLLTESNERL QLHLKERMAA LEEKNVLIQE SETFRKNLEE SLHDKERLAE EIEKLRSELD QLKMRTGSLI EPTIPRTHLD TSAELRYSVG SLVDSQSDYR TTKVIRRPRR GRMGVRRDEP KVKSLGDHEW NRTQQIGVLS SHPFESDTEM SDIDDDDRET IFSSMDLLSP SGHSDAQTLA MMLQEQLDAI NKEIRLIQEE KESTELRAEE IENRVASVSL EGLNLARVHP GTSITASVTA SSLASSSPPS GHSTPKLTPR SPAREMDRMG VMTLPSDLRK HRRKIAVVEE DGREDKATIK CETSPPPTPR ALRMTHTLPS SYHNDARSSL SVSLEPESLG LGSANSSQDS LHKAPKKKGI KSSIGRLFGK KEKARLGQLR GFMETEAAAQ ESLGLGKLGT QAEKDRRLKK KHELLEEARR KGLPFAQWDG PTVVAWLELW LGMPAWYVAA CRANVKSGAI MSALSDTEIQ REIGISNPLH RLKLRLAIQE MVSLTSPSAP PTSRTPSGNV WVTHEEMENL AAPAKTKESE EGSWAQCPVF LQTLAYGDMN HEWIGNEWLP SLGLPQYRSY FMECLVDARM LDHLTKKDLR VHLKMVDSFH RTSLQYGIMC LKRLNYDRKE LERRREASQH EIKDVLVWSN DRVIRWIQAI GLREYANNIL ESGVHGSLIA LDENFDYSSL ALLLQIPTQN TQARQILERE YNNLLALGTE RRLDESDDKN FRRGSTWRRQ FPPREVHGIS MMPGSSETLP AGFRLTTTSG QSRKMTTDVA SSRLQRLDNS TVRTYSC
Explore Liprin-alpha-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets